WO2003039539A3 - Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen - Google Patents

Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen Download PDF

Info

Publication number
WO2003039539A3
WO2003039539A3 PCT/EP2002/011350 EP0211350W WO03039539A3 WO 2003039539 A3 WO2003039539 A3 WO 2003039539A3 EP 0211350 W EP0211350 W EP 0211350W WO 03039539 A3 WO03039539 A3 WO 03039539A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
treatment
endothelin receptor
tumour diseases
diseases
Prior art date
Application number
PCT/EP2002/011350
Other languages
English (en)
French (fr)
Other versions
WO2003039539A2 (de
Inventor
Mathias Osswald
Dieter Dorsch
Werner Mederski
Christiane Amendt
Matthias Grell
Original Assignee
Merck Patent Gmbh
Mathias Osswald
Dieter Dorsch
Werner Mederski
Christiane Amendt
Matthias Grell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Mathias Osswald, Dieter Dorsch, Werner Mederski, Christiane Amendt, Matthias Grell filed Critical Merck Patent Gmbh
Priority to US10/495,108 priority Critical patent/US20050014769A1/en
Priority to JP2003541830A priority patent/JP2005510511A/ja
Priority to MXPA04004306A priority patent/MXPA04004306A/es
Priority to HU0402281A priority patent/HUP0402281A2/hu
Priority to BR0213684-8A priority patent/BR0213684A/pt
Priority to EP02802624A priority patent/EP1441721A2/de
Priority to CA002465744A priority patent/CA2465744A1/en
Publication of WO2003039539A2 publication Critical patent/WO2003039539A2/de
Publication of WO2003039539A3 publication Critical patent/WO2003039539A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Verwendung von Endothelin-Rezeptor-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Tumorerkrankungen.
PCT/EP2002/011350 2001-11-09 2002-10-10 Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen WO2003039539A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/495,108 US20050014769A1 (en) 2001-11-09 2002-10-10 Use of endothelin receptor antogonists for the treatment of tumour diseases
JP2003541830A JP2005510511A (ja) 2001-11-09 2002-10-10 腫瘍疾患を治療するためのエンドセリン受容体拮抗薬の使用
MXPA04004306A MXPA04004306A (es) 2001-11-09 2002-10-10 Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
HU0402281A HUP0402281A2 (hu) 2001-11-09 2002-10-10 Endotelin receptor antagonisták alkalmazása daganatos betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
BR0213684-8A BR0213684A (pt) 2001-11-09 2002-10-10 Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
EP02802624A EP1441721A2 (de) 2001-11-09 2002-10-10 Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
CA002465744A CA2465744A1 (en) 2001-11-09 2002-10-10 Use of endothelin receptor antagonists in the treatment of tumour diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10155076A DE10155076A1 (de) 2001-11-09 2001-11-09 Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
DE10155076.6 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003039539A2 WO2003039539A2 (de) 2003-05-15
WO2003039539A3 true WO2003039539A3 (de) 2003-11-06

Family

ID=7705184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011350 WO2003039539A2 (de) 2001-11-09 2002-10-10 Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen

Country Status (15)

Country Link
US (1) US20050014769A1 (de)
EP (1) EP1441721A2 (de)
JP (1) JP2005510511A (de)
KR (1) KR20050035181A (de)
CN (1) CN1585636A (de)
AR (1) AR037343A1 (de)
BR (1) BR0213684A (de)
CA (1) CA2465744A1 (de)
DE (1) DE10155076A1 (de)
HU (1) HUP0402281A2 (de)
MX (1) MXPA04004306A (de)
PL (1) PL369822A1 (de)
RU (1) RU2004117596A (de)
WO (1) WO2003039539A2 (de)
ZA (1) ZA200404544B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2005095972A2 (en) * 2004-03-19 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb)
ITMI20040874A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
KR100989141B1 (ko) * 2007-05-14 2010-10-20 경희대학교 산학협력단 시클로옥시게나제-2 저해제
WO2008140251A2 (en) * 2007-05-14 2008-11-20 University-Industry Cooperation Group Of Kyung Hee University Cyclooxygenase-2 inhibitors
JP5269086B2 (ja) 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
JP5285709B2 (ja) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
CN107021951B (zh) 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
AU2011326241B2 (en) 2010-11-09 2016-11-17 Ironwood Pharmaceuticals, Inc. sGC stimulators
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733626A1 (de) * 1995-03-18 1996-09-25 MERCK PATENT GmbH N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten
EP0755934A1 (de) * 1995-07-28 1997-01-29 MERCK PATENT GmbH Endothelin-rezeptor-antagonisten
EP0757039A1 (de) * 1995-08-02 1997-02-05 MERCK PATENT GmbH Endothelin-Rezeptor-Antagonisten
EP0758650A1 (de) * 1995-08-16 1997-02-19 MERCK PATENT GmbH Endothelin-Rezeptor-Antagonisten
WO1997013758A1 (de) * 1995-10-09 1997-04-17 MERCK Patent Gesellschaft mit beschränkter Haftung Pyridazinone als endothelin-rezeptor-antagonisten
WO1997019077A1 (de) * 1995-11-23 1997-05-29 MERCK Patent Gesellschaft mit beschränkter Haftung Endothelin-rezeptor-antagonisten
WO1997030996A1 (de) * 1996-02-24 1997-08-28 MERCK Patent Gesellschaft mit beschränkter Haftung N-(2,1,3-benzothia(oxa)diazolyl)-sulfonamide mit endothelinrezeptor-antagonistischer wirkung
WO1997030982A1 (de) * 1996-02-24 1997-08-28 MERCK Patent Gesellschaft mit beschränkter Haftung 2,1,3-benzothia(oxa)diazolderivate mit endothelinrezeptor-antagonistischer wirkung
DE19609597A1 (de) * 1996-03-12 1997-09-18 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19612101A1 (de) * 1996-03-27 1997-10-02 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
WO1998027077A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh 2,1,3-benzothia(oxa)diazolderivate und ihre verwendung als endothelin-rezeptor-antagonisten
WO1998027091A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-rezeptor-antagonisten als pestizide
WO1998041521A1 (de) * 1997-03-19 1998-09-24 Merck Patent Gmbh Endothelin-rezeptor-antagonisten
WO1998041515A1 (de) * 1997-03-15 1998-09-24 Merck Patent Gmbh Endothelin-rezeptor-antagonisten
WO1998042702A1 (de) * 1997-03-22 1998-10-01 Merck Patent Gmbh Endothelin-rezeptor-antagonisten
WO1998042709A1 (de) * 1997-03-21 1998-10-01 Merck Patent Gmbh Endothelin-rezeptor-antagonisten
WO1999005132A1 (de) * 1997-07-23 1999-02-04 Merck Patent Gmbh Benzothia(oxa)diazolderivate und ihre verwendung als endothelin-rezeptor-antagonisten
US6080774A (en) * 1995-10-11 2000-06-27 Bristol-Myers Squibb Company Substituted biphenylsulfonamide endothelin antagonists
WO2000036918A1 (en) * 1998-12-22 2000-06-29 Marine Polymers Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2228293A1 (en) * 1995-08-02 1997-02-13 John Duncan Elliott Endothelin receptor antagonists

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733626A1 (de) * 1995-03-18 1996-09-25 MERCK PATENT GmbH N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten
EP0755934A1 (de) * 1995-07-28 1997-01-29 MERCK PATENT GmbH Endothelin-rezeptor-antagonisten
EP0757039A1 (de) * 1995-08-02 1997-02-05 MERCK PATENT GmbH Endothelin-Rezeptor-Antagonisten
EP0758650A1 (de) * 1995-08-16 1997-02-19 MERCK PATENT GmbH Endothelin-Rezeptor-Antagonisten
WO1997013758A1 (de) * 1995-10-09 1997-04-17 MERCK Patent Gesellschaft mit beschränkter Haftung Pyridazinone als endothelin-rezeptor-antagonisten
US6080774A (en) * 1995-10-11 2000-06-27 Bristol-Myers Squibb Company Substituted biphenylsulfonamide endothelin antagonists
WO1997019077A1 (de) * 1995-11-23 1997-05-29 MERCK Patent Gesellschaft mit beschränkter Haftung Endothelin-rezeptor-antagonisten
WO1997030996A1 (de) * 1996-02-24 1997-08-28 MERCK Patent Gesellschaft mit beschränkter Haftung N-(2,1,3-benzothia(oxa)diazolyl)-sulfonamide mit endothelinrezeptor-antagonistischer wirkung
WO1997030982A1 (de) * 1996-02-24 1997-08-28 MERCK Patent Gesellschaft mit beschränkter Haftung 2,1,3-benzothia(oxa)diazolderivate mit endothelinrezeptor-antagonistischer wirkung
DE19609597A1 (de) * 1996-03-12 1997-09-18 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19612101A1 (de) * 1996-03-27 1997-10-02 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
WO1998027077A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh 2,1,3-benzothia(oxa)diazolderivate und ihre verwendung als endothelin-rezeptor-antagonisten
WO1998027091A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-rezeptor-antagonisten als pestizide
WO1998041515A1 (de) * 1997-03-15 1998-09-24 Merck Patent Gmbh Endothelin-rezeptor-antagonisten
WO1998041521A1 (de) * 1997-03-19 1998-09-24 Merck Patent Gmbh Endothelin-rezeptor-antagonisten
WO1998042709A1 (de) * 1997-03-21 1998-10-01 Merck Patent Gmbh Endothelin-rezeptor-antagonisten
WO1998042702A1 (de) * 1997-03-22 1998-10-01 Merck Patent Gmbh Endothelin-rezeptor-antagonisten
WO1999005132A1 (de) * 1997-07-23 1999-02-04 Merck Patent Gmbh Benzothia(oxa)diazolderivate und ihre verwendung als endothelin-rezeptor-antagonisten
WO2000036918A1 (en) * 1998-12-22 2000-06-29 Marine Polymers Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders

Also Published As

Publication number Publication date
BR0213684A (pt) 2004-10-26
EP1441721A2 (de) 2004-08-04
KR20050035181A (ko) 2005-04-15
CN1585636A (zh) 2005-02-23
US20050014769A1 (en) 2005-01-20
RU2004117596A (ru) 2005-05-27
MXPA04004306A (es) 2004-08-11
ZA200404544B (en) 2005-02-08
AR037343A1 (es) 2004-11-03
PL369822A1 (en) 2005-05-02
WO2003039539A2 (de) 2003-05-15
DE10155076A1 (de) 2003-05-22
JP2005510511A (ja) 2005-04-21
HUP0402281A2 (hu) 2005-02-28
CA2465744A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
WO2001030381A3 (de) Verwendung von csf-1-inhibitoren
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
WO2003080582A3 (de) Fredericamycin-derivate
AU2003300791A1 (en) Combination therapy for the treatment of pain
HK1079993A1 (en) Drugs for treating vascular diseases
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
AU2002254930A1 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
MXPA02009434A (es) Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion.
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
AU2003209542A8 (en) Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders
PL367401A1 (en) Utilization of buprenorphine in urinary incontinence therapy
GB0201025D0 (en) The treatment of degenerative diseases
AU2002311141A1 (en) The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
WO2004012732A3 (en) Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
MX2007004040A (es) Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
PT1474415E (pt) Derivados de benzimidazol substituídos em 1-fenilo-2- heteroarilo, o seu uso para a produção de fármacos para o tratamento de doenças imunológicas
WO2004002399A3 (en) Use of gaba-c receptor antagonists for the treatment of myopia
AU2002363367A1 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
WO2003028709A3 (en) Use of mannosamine derivatives for the stimulation of neurite growth

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002802624

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004306

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047007032

Country of ref document: KR

Ref document number: 2465744

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20028222520

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003541830

Country of ref document: JP

Ref document number: 10495108

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004/04544

Country of ref document: ZA

Ref document number: 200404544

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002363367

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002802624

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002802624

Country of ref document: EP